Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis.
Osteoporosis is a major public health problem. Oral bisphosphonates are effective for reducing the risk of osteoporotic fractures and are an important treatment option for patients at risk for this condition. Osteonecrosis of the jaw (ONJ) is uncommon among cancer patients who are receiving high-dose intravenous bisphosphonates and rarely is seen among patients who are taking oral bisphosphonates for osteoporosis. Dentists play an important role in discussing the implications of the overall dental and medical treatment plans with both patients and physicians. The low risk of ONJ with oral bisphosphonates should be balanced against the benefits of osteoporosis therapy.
Jeffcoat
Marjorie
M
University of Pennsylvania School of Dental Medicine, Philadelphia, USA.
Watts
Nelson B
NB
D000284:Administration, Oral; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D010020:Osteonecrosis / Q000139:chemically induced*; D010024:Osteoporosis / Q000188:drug therapy*; D012307:Risk Factors
D004164:Diphosphonates